In the NewsAugust 9, 2024Karius to Expand Agnostic Pathogen Detection Capability to RNA GenomesMay 16, 2024Karius snares FDA breakthrough tag for genomic infectious disease blood testMay 16, 2024Karius Test Receives FDA Breakthrough Device DesignationMay 13, 2024The New Era of Life Sciences 2024May 2, 2024Liquid Biopsy Company Karius Raised $100M To Expand Its Test For Detecting Over 1,000 PathogensApril 11, 2024Top Medical Testing Startups For Personalised Health InsightsLoad morePress ReleasesAugust 8, 2024Karius Secures BARDA Contract to Expand Agnostic Detection of PathogensMay 16, 2024Karius Test® Receives FDA Breakthrough Device Designation to Aid in the Diagnosis of Infectious DiseaseMay 2, 2024Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance CrisisOctober 10, 2023Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood CancerAugust 10, 2023Karius Inc. Adds Dr. Norman Sharpless, Former National Cancer Institute Head, and Elizabeth O’Farrell, Eli Lilly Veteran, to its Board of DirectorsAugust 2, 2023Karius Test®, a Liquid Biopsy for Infectious Diseases, Incorporated into Diagnostics Recommendation in the 2023 Duke-ISCVID Criteria for Infective Endocarditis
May 2, 2024Liquid Biopsy Company Karius Raised $100M To Expand Its Test For Detecting Over 1,000 Pathogens